You are here
Budesonide Provides Lasting Relief for Patients With Crohn's Disease
Four double-blind, placebo-controlled trials were conducted with identical protocols in which patients with Crohn's Disease, and medically induced remission, received a treatment of oral budesonide for 12 months. Results showed that budesonide taken at 6 mg/day is effective for prolonging time to relapse and for significantly reducing rates of relapse.
"Long-term treatment with budesonide is well-tolerated and the frequency and types of adverse events are similar to placebo," states lead researcher,William J. Sandborn, MD. "Safety of a long-term medication is obviously important, but how well a patient tolerates their medication is also important and can affect patient adherence to therapy."
Source: American Journal of Gastroenterology